论文部分内容阅读
目的分析复方甘草酸苷对新生儿高胆红素血症的疗效及安全性。方法 2008年6月～2011年6月,158例新生儿高胆红素血症随机分为两组,对照组79例采用常规治疗,观察组79例在对照组基础上采用复方甘草酸苷治疗,对比观察治疗前后两组的临床疗效、血清总胆红素(TBIL)、谷草转氨酶(AST)和谷氨酰转移酶(GGP)水平的变化。结果观察组的治愈率明显高于对照组(P﹤0.05)。两组治疗后TBIL、AST和GGP水平均较治疗前下降,差异有统计学意义(P﹤0.05)。观察组治疗后TBIL、AST和GGP水平均低于同期对照,差异有统计学意义(P﹤0.05)。两组不良反应发生率比较差异无统计学意义(P﹥0.05)。结论复方甘草酸苷对新生儿高胆红素血症进行治疗,能够明显提高疗效,降低TBIL、AST和GGP水平,不良反应少,值得临床推广应用。
Objective To analyze the efficacy and safety of compound glycyrrhizin on neonatal hyperbilirubinemia. Methods From June 2008 to June 2011, 158 cases of neonatal hyperbilirubinemia were randomly divided into two groups, 79 cases in control group were treated routinely, 79 cases in observation group were treated with compound glycyrrhizin on the basis of control group The changes of clinical efficacy, serum total bilirubin (TBIL), aspartate aminotransferase (AST) and glutamase transferase (GGP) levels in both groups were observed before and after treatment. Results The cure rate of the observation group was significantly higher than that of the control group (P <0.05). After treatment, the levels of TBIL, AST and GGP in both groups were significantly lower than those before treatment (P <0.05). The levels of TBIL, AST and GGP in the observation group after treatment were lower than those in the same period, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Compound glycyrrhizin can effectively improve neonatal hyperbilirubinemia, reduce the levels of TBIL, AST and GGP, and have fewer adverse reactions. It is worthy of clinical application.